Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2566)

(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 15, 2026; (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (3) AMENDMENTS TO THE ARTICLES OF ASSOCIATION; (4) ABOLISHMENT OF THE SUPERVISORY COMMITTEE; (5) APPOINTMENT OF EMPLOYEE REPRESENTATIVE DIRECTOR; AND (6) FINAL DIVIDEND

The board of directors (the "**Board**") of Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (杭州九源基因生物醫藥股份有限公司) (the "**Company**") is pleased to announce the poll results of the annual general meeting (the "**AGM**") held on Monday, June 15, 2026.

For details of the resolutions considered at the AGM, the shareholders of the Company (the "**Shareholders**") may refer to the notice of the AGM and the Company's circular both dated April 24, 2026 (the "**Circular**"). Unless otherwise defined, capitalized terms in this announcement shall have the same meanings as those defined in the Circular.

CONVENING AND ATTENDANCE OF THE AGM

The AGM was held as an on-site meeting at Conference Room 3, No. 23, Eighth Street, Baiyang Street, Qiantang District, Hangzhou City, Zhejiang Province, PRC on Monday, June 15, 2026.

The AGM was convened by the Board and hosted by Mr. Fu Hang, the chairman of the Board. All the directors and supervisors of the Company attended the AGM, either in person or online.

The convention of the AGM was in compliance with the requirements of the applicable PRC laws and regulations, the Listing Rules, and the articles of association of the Company (the "**Articles of Association**"). All the proposed resolutions as set out in the notice of the AGM were tabled before the AGM for Shareholders' consideration and approval, and were put to vote by way of poll.

POLL RESULTS OF THE AGM

As at the date of the AGM, the total number of issued Shares and Shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM was 241,516,400 (excluding 3,882,400 treasury shares at the date of this announcement). As at the date of the AGM, there were (i) 3,882,400 treasury shares held by the Company (including any treasury Shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited) and as such no voting rights of treasury Shares have been exercised at the AGM; and (ii) no Shares repurchased by the Company which are pending cancellation. The number of Shareholders and authorized proxies attended the AGM was 1. Shareholders and authorized proxies holding an aggregate of 117,720,987 Shares attended the AGM, representing approximately 48.74% of the total number of issued Shares with voting rights (excluding treasury shares).

Save as disclosed above, to the best knowledge, information and belief of the Board, having made reasonable inquiries (i) there was no restriction on any Shareholder casting votes on any proposed resolution at the AGM; (ii) no Shareholder has a material interest in the matters considered at the AGM and was required under the Listing Rules to abstain from voting at the AGM; (iii) there were no Shares entitling the holders to attend and abstain from voting in favour of any resolution proposed at the AGM as set out in Rule 13.40 of the Listing Rules; and (iv) no party has stated any intention in the Circular to vote against or abstain from voting on any resolution proposed at the AGM.

At the AGM, the following resolutions were considered and passed by registered poll and the poll results are set out as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the 2025 Report of the Board.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)
2.	To consider and approve the 2025 Report of the Independent Non-executive Directors.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)
3.	To consider and approve the 2025 Report of the Supervisory Committee.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)
4.	To consider and approve the 2025 Audited Consolidated Financial Statements and the 2025 Independent Auditor's Report.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)
5.	To consider and approve the 2025 Annual Report.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)
6.	To consider and approve the 2025 ESG Report.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)
7.	To consider and approve the 2025 Profit Distribution Plan.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)

ORDINARY RESOLUTIONS		Number of Votes (%)		
		For	**Against**	**Abstain**
8.	To consider and approve the re-appointment of Ernst & Young and Ernst & Young Hua Ming LLP as the external auditors of the Company for the year 2026, for a term until the conclusion of the next annual general meeting of the Company, and the Board is authorized to determine the specific remuneration.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)
9.	To consider and approve the Directors' remuneration for the year 2026.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)
10.	To consider and approve proposed appointment of independent non-executive Director.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)
11.	To consider and approve proposed amendments to the Rules of Procedures for the Board of Directors.	117,381,987 (99.71%)	339,000 (0.29%)	0 (0.00%)
12.	To consider and approve proposed amendments to the Rules of Procedures for the Shareholders' General Meeting.	117,381,987 (99.71%)	339,000 (0.29%)	0 (0.00%)
SPECIAL RESOLUTIONS		**Number of Votes (%)**		
		For	**Against**	**Abstain**
13.	To consider and approve proposed change of the scope of business.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)
14.	To consider and approve proposed abolishment of the Supervisory Committee.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)
15.	To consider and approve proposed amendments to the Articles of Association.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)
16.	To consider and approve the Issue Mandate.	117,358,587 (99.69%)	362,400 (0.31%)	0 (0.00%)
17.	To consider and approve the Repurchase Mandate.	117,720,987 (100.00%)	0 (0.00%)	0 (0.00%)

As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 12, such resolutions were duly passed as ordinary resolutions.

As more than two-thirds of the votes were cast in favour of each of the resolutions numbered 13 to 17, such resolutions were duly passed as special resolutions.

FINAL DIVIDEND

As the resolution numbered 7 regarding the 2025 Profit Distribution Plan was approved at the AGM, the Board is pleased to announce that the following details regarding the distribution of a final dividend of RMB0.57 (tax inclusive) for every 10 Shares (the "**Final Dividend**") to all Shareholders based on the total share capital as of the record date for profit distribution and dividend payment.

For the purpose of determining the entitlement to the Final Dividend for the year of 2025, the register of members of H Shares will be closed from Monday, June 22, 2026 to Wednesday, June 24, 2026 (both days inclusive), during which period no transfer of H Shares will be registered. In order to qualify for the Final Dividend, all completed share transfer documents, accompanied by the relevant share certificates, must be lodged with the Company's H share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712 –1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration no later than 4:30 p.m. on Thursday, June 18, 2026.

The Final Dividend will be denominated and declared in RMB, with the dividend on H Shares to be paid in Hong Kong dollars. The exchange rate to be used for the conversion of the cash dividend from RMB to HKD will be based on the average of the central parity rate of the RMB against HKD (i.e. RMB1 against HK$1.1498) exchange rate announced by the People's Bank of China for the five business days prior to the date of declaration of the Final Dividend. Accordingly, the Final Dividend payable per 10 H Shares are HK$0.6554 (before tax).

Withholding and Payment of Enterprise Income Tax on behalf of Overseas Non-Resident Enterprise Shareholders

Pursuant to the applicable provisions of the Enterprise Income Tax Law of the PRC (《中華人民共和國企業所得稅法》) and its implementing rules and the requirements under the Notice on the Issues Concerning Withholding and Payment of the Enterprise Income Tax on the Dividends Paid by Chinese Resident Enterprises to H Share Holders Who Are Overseas Non-resident Enterprises (Guo Shui Han [2008] No. 897) issued by the State Taxation Administration (國家稅務總局《關於中國居民企業向境外H股非居民企業股東派發股息代扣代繳企業所得稅有關問題的通知》(國稅函[2008]897號)), the Company will withhold and pay enterprise income tax at the rate of 10% when it distributes the final dividends to overseas non-resident enterprise Shareholders (including any H Shares of the Company registered in the name of HKSCC Nominees Limited, but excluding any H Shares of the Company registered in the name of HKSCC Nominees Limited which are held by China Securities Depository and Clearing Corporation Limited as a nominee shareholder on behalf of investors who invest in H Shares of the Company through H share "**full circulation**"). The non-resident enterprise Shareholders may, on their own or through an authorised agent, apply to the competent tax authorities of the Company to enjoy the tax preferential treatments under the tax treaty (arrangement) by providing information of them being the actual beneficiaries of the tax treaty (arrangement).

Withholding and Payment of Individual Income Tax on behalf of Overseas Individual Shareholders

Pursuant to the applicable provisions of the Individual Income Tax Law of the PRC (《中華人民共和國個人所得税法》) and its implementing rules, the Notice of the Ministry of Finance and the State Administration of Taxation on Some Policy Issues Regarding Individual Income Tax (Cai Shui Zi [1994] No.20)(《財政部、國家税務總局關於個人所得税若干政策問題的通知》(財税字[1994]20號)) and other relevant laws and regulations and requirements under normative documents, the dividend and bonus incomes received by individual aliens from the foreign-invested enterprises are temporarily exempted from individual income tax.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

With regard to the ordinary resolution numbered 10 above, Dr. Huang Wenli (黃文禮) ("**Dr. Huang**") has been elected as independent non-executive Director of the first session of the Board at the AGM. The term of office of Dr. Huang will continue until the expiration of the term of office of the first session of the Board, with effect from June 15, 2026. Pursuant to the Articles of Association, Dr. Huang is eligible for re-election upon the expiry of his term. Pursuant to the requirements of Rule 13.51(2) of the Listing Rules, the details of the biographies of Dr. Huang and other information relating to his appointment are set out in the Circular. As of the date of this announcement, there is no change in such information.

The Board wishes to express its warm welcome to Dr. Huang for joining the Board.

ABOLISHMENT OF THE SUPERVISORY COMMITTEE

As the resolution numbered 14 regarding the abolishment of the Supervisory Committee was approved at the AGM, the Company hereby announces that the Company has abolished the Supervisory Committee, effective from June 15, 2026. The functions and powers of the Supervisors shall be exercised by the audit committee of the Board. Mr. Ye Jiancai, Mr. Xu Feihu and Ms. Zhao Fei will no longer serve as Supervisors of the Company, the relevant provisions in the Company's governance policies concerning the Supervisors and the Supervisory Committee shall be abolished accordingly. Each of the Supervisors has confirmed that he/she has no disagreement with the Company and the Board in any respect, and there is no other matter that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Company would like to take this opportunity to express its sincere gratitude to the Supervisors for their contributions to the Company during their tenure of office as the Supervisor of the Company.

ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR

The Board hereby announces that, at the employee representative meeting of the Company convened on June 15, 2026, Mr. Xu Feihu (徐飛虎) has been elected as the employee representative Director of the first session of the Board. The term of office of Mr. Xu will continue until the expiration of the term of office of the first session of the Board. Pursuant to the Articles of Association, the employee representative Director shall be elected by the Company's employees at an employee representative meeting or through other means of democratic election, without requiring consideration and approval at a general meeting. Accordingly, the election of Mr. Xu as an employee representative Director became effective on June 15, 2026.

The biographical details of Mr. Xu are as follows:

Mr. Xu Feihu (徐飛虎), aged 48, was appointed as our Supervisor from November 2023 to June 2026. He was responsible for overseeing our operational and financial activities.

Mr. Xu has served in our Company in charge of project evaluation and management of intellectual property since August 2003. He served as a researcher and then a manager of our Company from August 2003 to January 2010. He then served as a deputy chief engineer and then chief engineer of our Company from February 2010 to December 2015. After that, Mr. Xu served as the manager of the information and intelligence department and then the manager of the development department of our Company from January 2016 to February 2023. Mr. Xu has served as our deputy director of intellectual property and manager of our development department since March 2023 and he is currently the director of intellectual property and manager of our development department.

Mr. Xu obtained a bachelor's degree in bioscience and technology and a master's degree in biophysics from Zhejiang University in June 2000 and June 2003, respectively. Mr. Xu was recognized as a senior engineer in development of new drugs by Zhejiang Province Human Resources and Social Security Department in December 2011 and a National Patent Information Practition Talent (全國專利信息實務人才) by the China National Intellectual Property Administration (國家知識產權局) in April 2016. He was also awarded the China Patent Excellence Award (中國專利優秀獎) both in November 2011 and November 2015 by the China National Intellectual Property Administration.

Save as disclosed above, Mr. Xu (i) has no interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not hold any other positions with the Company or other members of the Group; (iii) does not have any relationship with any Directors, senior management, substantial Shareholders (as defined in the Listing Rules) or controlling Shareholders (as defined in the Listing Rules); (iv) does not hold any directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (v) does not have any other major appointments and professional qualifications.

Save as disclosed above, there are no other matters relating to the appointment of Mr. Xu that need to be brought to the attention of the Shareholders and the Stock Exchange, nor is there any other information required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Company will not enter into a service contract with Mr. Xu with respect to his appointment as an employee representative Director. Mr. Xu is entitled to an annual basic remuneration, which is determined with reference to his roles and responsibilities within the Company and in accordance with the Company's remuneration and performance assessment policies.

The Board wishes to express its warm welcome to Mr. Xu for joining the Board.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

As the resolution numbered 15 regarding the amendments to the Articles of Association was approved at the AGM, the amendments to the Articles of Association took effect after the adoption of resolution 15 at the AGM on June 15, 2026. The Company will undertake necessary filing procedures in Hong Kong and the PRC in due course. The full text of the amended Articles of Association will be published on the websites of the Stock Exchange at www.hkexnews.hk and the Company at www.china-gene.com. Shareholders of the Company should be aware that the English version of the Articles of Association is a translation from the Chinese version. The Chinese version of the Articles of Association shall prevail in the case of discrepancies and/or inconsistencies between the two versions.

SCRUTINEERS

The H Share Registrar of the Company, Computershare Hong Kong Investor Services Limited, two Shareholders' representatives, and one supervisor of the Company served as the scrutineers of the AGM for scrutinizing and counting votes.

By order of the Board
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
FU Hang
Executive Director, Chairman of the Board and General Manager

Hangzhou, PRC, June 15, 2026

As of the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Xu Feihu (徐飛虎) as employee representative director; (iii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iv) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀), Dr. Zhou Demin (周德敏) and Dr. Huang Wenli (黃文禮) as independent non-executive directors.